Phase II Trial of CPX (Cytarabine:Daunorubicin) Liposome Injection in Patients >/=60 Years of Age With AML Previously Untreated By Intensive Chemotherapy
Latest Information Update: 26 Feb 2024
Price :
$35 *
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 19 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 19 Dec 2022 Planned primary completion date changed from 22 Nov 2022 to 22 Apr 2024.
- 30 Nov 2020 Planned End Date changed from 1 Oct 2022 to 1 Dec 2022.